CHRO (Channel Therapeutics) Debt-to-Revenue : N/A (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Channel Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.29 Mil. Channel Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Channel Therapeutics's annualized Revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

Channel Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Channel Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Channel Therapeutics Debt-to-Revenue Chart

Channel Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

1.21

N/A

Channel Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial									N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Channel Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Channel Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Channel Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Channel Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Channel Therapeutics's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Channel Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Channel Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.269	+	0)	/	N/A
	=	N/A

Channel Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.288	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Channel Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Channel Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Channel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728

Website

https://www.channeltherapeutics.com

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Channel Therapeutics Headlines

From GuruFocus

Chromocell Announces Stock Repurchase Plan

By Marketwired • 08-07-2024

Ikarian Capital, LLC's Strategic Acquisition of Channel Therapeutics Corp Shares

By GuruFocus News • 02-14-2025